13th International
symposium on MPS and
related diseases
13th International
symposium on MPS and
related diseases
13th International
symposium on MPS and
related diseases
13th International
symposium on MPS and
related diseases
Mogam Culture code
Non-profit research institute
Korea's first privately-funded non-profit research institute
Helping society through the development of life science technology
Creation of a continuous research environment
Achievements through research activities
Developing the world's 3rd hepatitis B vaccine
Developing the world's 1st vaccine for hemorrhagic fever with renal syndrome (HFRS)
Developing the world's 2nd varicella vaccine
Development of innovative drugs using AI
Developing treatments and vaccines for rare diseases, autoimmune diseases, infectious
diseases, cancers, etc.
Novel drug development using artificial intelligence
Pursuing the goals of developing new drugs and improving public health on a global scale
Based on scientific identification and
understanding of life phenomena, we are
constantly
striving to leap into a research
center equipped with new drug development
capabilities
View of the former MOGAM Institute for Biomedical Research
The MOGAM Institute for Biomedical Research (MIBR), Korea’s first privately owned non-profit research institute, was established in 1984 by Dr. Young-sup Huh using all of the profit generated from the successful development of the Hepatitis B vaccine by GC Biopharma.
MIBR has made significant contributions to Korea’s biomedical industry by successfully producing vaccines, diagnostic kits, and important recombinant proteins. MIBR led to the development of the third in the world Hepatitis B vaccine, the first Epidemic hemorrhagic fever vaccine, and the second chickenpox vaccine.
View of the former R&D center
The 30th anniversary of
Our mission is to help those suffering from disease by developing innovative therapies. MIBR will lead a novel drug development paradigm through the accumulated know-how.
View of current R&D center
Rising Up
Seeking to become a global powerhouse for drug discovery
Dr.Hyunjin Shin became the 12th President of the MIBR
Dr.Sun Kim became the 11th President of the MIBR
MOU with Artificial Intelligence Institute of Seoul National University and GC Biopharma
Dr.Hyunjin Shin became the Vice President of the MIBR inauguration of AI-based novel drug development institute
Obtained NDA approval of new varicella vaccine (Barycela)
Dr.Jae Uk Jeong became the 10th President of the MIBR
Dr.Eui-Cheol Jo became the 9th President of the MIBR
The Name was changed to MOGAM Institute for Biomedical Research(MIBR)
Obtained NDA approval of avian influenza(AI) virus vaccine
Obtained NDA approval of quadrivalent flu vaccine
Awarded 16th New Drug Technology of Korea (NeulaPEG)
Dr.Senyon Choe became the 8th President of the MBRI
Maturity
Seeking to become a global powerhouse for drug discovery
Phase II IND approval for avian influenza (AI) virus vaccine
Dr.Eun-Chul Huh became the 7th President of the MBRI
MFDS IND approved for phase II/III in neutropenia
MFDS IND approved for an anti-angiogenic cancer drug
MFDS IND approved for natural killer (NK) cell therapy
Minister Award at the Health Industry Technology Awards (for the anti-angiogenic cancer drug)
MFDS IND approved for an avian influenza (AI) vaccine
FDA IND approved for the anti-angiogenic cancer drug
MFDS IND approved for the neutropenia drug
Dr. Yeup Yoon became the 6th President of the MBRI
Collaboration with the U.S. MD Anderson Cancer Center
Redesignation of WHO Collaborating Research Center (for vaccines and diagnostic reagents)
MOU with German Fraunhofer-IME for joint research
Developed a diagnostic reagent for SARS
Growth
Seeking to become a global powerhouse for drug discovery
Signed an agreement with the Chinese ICDC to conduct joint research into diagnostic reagents
Established cord blood storage technology
Built and started to run a bio pilot plant
Dr. Du-hong Park became the 5th President of the MBRI
Dr. Su-il Jeong became the 4th President of the MBRI
Redesignation of WHO Collaborating Research Center (for vaccines and diagnostic reagents)
Established the MOGAM biotechnology award sat the Korean society for molecular biology
Beginning
Seeking to become a global powerhouse for drug discovery
Developed the world's 2nd varicella vaccine (Suduvax)
Dr. Hong-mo Moon became the 3rd President of the MBRI
Developed the world's 1st vaccine for epidemic hemorrhagic fever (Hantavax)
Developed an AIDS (HIV-1) diagnostic reagent
First designation of WHO Collaborating Research Center (for vaccines and diagnostic reagents)
Dr. Seung-bok Baek became the 2nd President of the MBRI
Renamed the MOGAM Biotechnology Research Institute (MBRI)
Selected as a military research institute
Dr.Gyeong-ho Kim became the 1st President of the MBRI
Established as the Green Cross Research Foundation, the nation's first non-profit research institute approved by the Ministry of Science and Technology
Dr. Mogam Young-sup Huh
Dr. Mogam Young-sup Huh (Founder)
“Even when the dust piles up,
we must let it pile up on our soil...”
The first President Dr. Mogam Young-sup Huh was a pioneer in the localization of essential medicines. He devoted his life to the development of novel drugs beneficial to the health of the people, rather than focusing on making a profit.
Dr. Huh had been deeply concerned about the health environment in Korea while studying in Germany in the 1960s. After returning to Korea in 1970, he established Green Cross (currently GC Biopharma) and strived to localize essential medicines that had been imported from foreign countries. He laid the foundation for life science research with funds raised through the successful development of drugs such as a hepatitis B vaccine. He also founded today’s MOGAM Institute for Biomedical Research, a private research foundation, to contribute to the promotion of national science and technology and give back to society.
“Even when the dust piles up, we must let it pile up on our soil...”
These were the first President Dr. Mogam Young-sup Huh’s words with his philosophy that, even if the situation may be harsh, research achievements and manpower will remain in the country only when research institutes are established in Korea.
Dr. Mogam Young-sup Huh (Founder)
The first President Dr. Young-sup Huh's pen name which means enriching the Earth
As a CEO who completed a Ph.D. course at RWTH Aachen University in Germany, Dr. Huh successfully led the company, pioneering the biotechnology industry in Korea, which had been previously unexplored. He made a number of contributions to promoting friendly cooperation between Korea and Germany through activities among private diplomatic organizations. This was recognized by his receiving the “Ehren senator” title, the most honorable title that RWTH Aachen University in Germany can confer, as a foreigner for the first time since the school's opening.
Also, Dr. Huh did not hesitate to support Korean students and research foundations in Korea. When he heard the news from RWTH Aachen University in Germany, which is often referred to as the “European MIT,” that there were not enough reading rooms where students could study freely, he established "MOGAM Haus" in 2007 with his personal donation of EUR 1 million. Dr. Mogam Young-sup Huh, who passed away in 2009 at the age of 68, set a social example until the very end of his life by donating two-thirds of his stock and legacy to scholarship and research foundations.
Dr. Huh devoted his life to creating a sustainable biopharmaceutical industry for the benefit of the Korean people. He was an excellent CEO in the biopharmaceutical field and an entrepreneur who always emphasized corporate social responsibility. The achievements of Dr. Mogam Young-sup Huh are of great significance in the improvement of the lives of people around the world, and across borders.
Biography
Chairman of the Korean-German Chamber of Commerce and Industry (2007 - 2009)
Donation for the MOGAM Haus at RWTH Aachen University in Germany
Chairman of the Korea Support Committee (KSC) of the International Vaccine Institute (IVI) (2005 - 2008)
4th Chairman of the Korea Industrial Technology Association (KOITA) (2003 - 2008)
Awarded with Ehren Senator by RWTH Aachen University in Germany
Vice-chairman of the Federation of Korean Industries (2001 - 2009)
President of the Koreanisch-Deutsche Gesellschaft (KDG, Korean-German Association) (2000 - 2009)
16th President of the Korea Pharmacy Association (1997 - 1999)
First Chairman of the Korea Organism Industry Association (1994 - 1997)
President and CEO of GC Pharma (1992 - 2009)
Chairman of the Korea Genetic Engineering Research Association (1987 - 1994)
Chairman of the MOGAM Institute for Biomedical Research (1984 - 2009)
President and CEO of GC Pharma
Joined GC Pharma
Obtained an Honorary Doctorate in Engineering from Hanyang University
Completed a Ph.D. course at RWTH Aachen University, Germany
Diploma at RWTH Aachen University, Germany
B.S., College of Engineering, Seoul National University
Received the Order of Science and Technology Merit, Creation Medal
Received the 22nd Inchon Award
Received the Distinguished Service Cross in Germany
Won the Korean CEO Grand Prize
Received the Order of Civil Merit, Peony Medal
Received the Silver Tower Order of Industrial Service Merit
Received the Stone Tower Order of Industrial Service Merit
The Board of Directors is proven leaders in
business and non-profit communities. They are
committed to
the MIBR’s mission and bring a range
of skills and perspectives in cutting-edge research
and innovation.
Il-Sup Huh
Chairman, Board
DongJip Kim
Director, Board
YungBog Chae
Director, Board
KwangSoon Shin
Director, Board
InSoon Han
Director, Board
YungJue Bang
Director, Board
Doo-Hong Park
Director, Board
ChanHee Lee
Director, Board
EunChul Huh
Director, Board
HyunJin Shin
Director, Board
Chansup Kim
Auditor, Board
MIBR has the Scientific Advisory Board with
the best scholars in the field of artificial intelligence.
SAB members provide
scientific advice and knowledge
on artificial intelligence-based drug discovery strategies,
and based on this,
MIBR is taking strong steps
toward novel drug discovery.
Prof. Jaewoo Kang, Ph.D
Professional Experience
·Dept. of Computer Science and Engineering, Korea University
·Vice President of program in Bioinformatics in Korea University
·Vice President of KIISE Data Base Society
·Board member of KIISE Artificial Intelligence Society
·Chief Executive Officer, AIGEN Sciences Inc.
Research & Awards
·Best Performer, BioCreative VII 2021
·Best Performer, BioASQ Task 8B-Phase B (A Bio-medical QA Challenge) 2020
·Best Performer, BioASQ Task 7B-Phase B (A Bio-medical QA Challenge) 2019
·Best Performer, Multi-targeting Drug DREAM Challenge 2018
·Lee et al., BioBERT: a pre-trained biomedical language representation model for biomedical text mining, Bioinformatics 2020 (3,400 citation)
Prof. Jaewoo Kang, Ph.D
Prof. Jinwoo Shin, Ph.D
Professional Experience
·The School of Electrical Engineering at KAIST and chair professor in Kim Jaechul Graduate School of AI
·Consulting in Samsung Advanced Institute of Technology
·Consulting in LG Energy Solution
·NeurIPS Senior Area Chair
·ICML/ICLR Area Chair
Research & Awards
·ACM SIGMETRICS Test-time Award, 2019
·Bloomberg Scientific Research Award, 2015
·ACM SIGMETRICS Rising Star Award, 2015
·Best Publication Award in INFORMS Applied Probability Society, 2013
·George M. Sprowls Award from MIT EECS Department (for the best doctoral thesis in MIT CS), 2010
Prof. Jinwoo Shin, Ph.D